Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach

被引：0
|
作者：
Loong, H. H. [1 ]
Mo, F. [1 ]
Li, L. [2 ]
Lee, C. [3 ]
Lam, K-C. [2 ]
Koh, J. [1 ]
Chiu, P. [4 ]
Teoh, A. [4 ]
Chan, A. T. C. [1 ]
Ng, E. [4 ]
Yeo, W. [1 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[3] United Christian Hosp, Dept Oncol, Hong Kong, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
402P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] OVERALL SURVIVAL AND HOSPITALIZATION RATES IN MEDICARE PATIENTS DIAGNOSED WITH ADVANCED NSCLC TREATED WITH BEVACIZUMAB- PACLITAXEL-CARBOPLATIN VS PACLITAXEL-CARBOPLATIN: A RETROSPECTIVE COHORT STUDY
    Langer, Corey J.
    Ravelo, Arliene
    Hazard, Sebastien
    Guerin, Annie
    Latremouille-Viau, Dominick
    Ionescu-Ittu, Raluca
    Wu, Eric Q.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S877 - S877
  • [32] Phase II study comparing paclitaxel-carboplatin alone with paclitaxel-carboplatin plus bevacizumab in previously untreated Japanese patients with advanced-stage non-squamous non-small cell lung cancer (NSCLC)
    Asahina, Hajime
    Kunitoh, Hideo
    Ichinose, Yukito
    Horai, Takeshi
    Nishiwaki, Yutaka
    Hida, Toyoaki
    Yamamoto, Nobuyuki
    Kawahara, Masaaki
    Saijo, Nagahiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S285 - S285
  • [33] Preliminary results: Phase II study of gefitinib in combination with paclitaxel and carboplatin as second-line therapy for advanced overian adenocarcinoma
    Pautier, P.
    Joly, F.
    Kerbrat, P.
    Bougnoux, P.
    Fumoleau, P.
    Petit, T.
    Rixe, O.
    Ringeisen, F.
    Lhomme, C.
    Kalla, S.
    ANNALS OF ONCOLOGY, 2004, 15 : 127 - 128
  • [34] Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers
    Karapanagiotou, E.
    Pandha, H. S.
    Hall, G.
    Chester, J.
    Melcher, A.
    Coffey, M.
    de Bono, J.
    Gore, M. E.
    Nutting, C. M.
    Harrington, K. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Phase II study of carboplatin and paclitaxel in patients with advanced upper gastrointestinal cancers
    Philip, PA
    Gadgeel, S
    Hussain, M
    Zalupski, MM
    Shields, AF
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 141 - 141
  • [36] A phase II study of alternating paclitaxel and carboplatin in patients with advanced ovarian cancer
    Adams, M
    Mort, D
    Coleman, R
    Wiliams, L
    Evans, A
    Thompson, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 496 - 496
  • [37] GYN 4: phase I study of BIBF 1120 in combination with paclitaxel/carboplatin in patients with advanced gynecological malignancies
    Huober, J.
    Pfisterer, J.
    Wimberger, P.
    Loibl, S.
    Stopfer, P.
    du Bois, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S11 - S11
  • [38] Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients ( pts) with BRAF-mutant advanced cancer
    Kato, Shumei
    Janku, Filip
    Piha-Paul, Sarina Anne
    Naing, Aung
    Karp, Daniel D.
    Tsimberidou, Apostolia Maria
    Subbiah, Vivek
    Zinner, Ralph
    Hwu, Wen-Jen
    Javle, Milind M.
    Parkhurst, Kristin L.
    Ramzanali, Nishma M.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Chae, Young Kwang
    Kim, Kevin
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] A Phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma
    Akerley, W
    Rathore, R
    Ready, N
    Leone, L
    Sikov, W
    Safran, H
    Kennedy, T
    CANCER, 2002, 95 (09) : 2000 - 2005
  • [40] Paclitaxel-carboplatin combination chemotherapy in advanced breast cancerAccumulating evidence for synergy, efficacy, and safety
    G. Pentheroudakis
    E. Razis
    A. Athanassiadis
    N. Pavlidis
    G. Fountzilas
    Medical Oncology, 2006, 23 : 147 - 160
12345